Distinguishing characteristics of exposure to biguanide and sulfonylurea anti-diabetic medications in the United States.
Abdominal Pain
/ drug therapy
Acidosis
/ drug therapy
Adolescent
Adult
Aged
Child
Creatinine
Diabetes Mellitus
/ chemically induced
Diarrhea
Dizziness
Humans
Hypoglycemia
/ drug therapy
Hypoglycemic Agents
/ adverse effects
Metformin
/ adverse effects
Middle Aged
Nausea
/ drug therapy
Retrospective Studies
Sulfonylurea Compounds
/ adverse effects
Tremor
United States
/ epidemiology
Vertigo
/ drug therapy
Vomiting
/ drug therapy
Young Adult
Biguanide poisoning
Diabetes
National Poison Data System
Prediction
Sulfonylurea poisoning
Journal
The American journal of emergency medicine
ISSN: 1532-8171
Titre abrégé: Am J Emerg Med
Pays: United States
ID NLM: 8309942
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
28
01
2022
revised:
13
03
2022
accepted:
13
03
2022
pubmed:
11
4
2022
medline:
21
5
2022
entrez:
10
4
2022
Statut:
ppublish
Résumé
Biguanides and sulfonylureas are anti-hyperglycemic drugs commonly used in the United States. Poisoning with these drugs may lead to serious consequences. The diagnosis of biguanide and sulfonylurea poisoning is based on history, clinical manifestations, and laboratory studies. This study is a six-year retrospective cohort analysis based on the National Poison Data System. Clinical effects of 6183 biguanide and sulfonylurea exposures were identified using binary logistic regression. The mean age of patients with biguanide and sulfonylurea exposure was 39.27 ± 28.91 and 28.91 ± 30.41 years, respectively. Sulfonylurea exposure is most commonly seen via unintentional exposure, while biguanide exposure frequently occurs as a result of intentional ingestion. Minor and moderate outcomes commonly developed following biguanide and sulfonylurea exposure, respectively. Sulfonylurea exposure was less likely to develop clinical effects abdominal pain, metabolic acidosis, diarrhea, nausea, vomiting, and elevated creatinine than patients ingesting biguanides. However, sulfonylurea exposure was more likely to cause dizziness or vertigo, tremor, drowsiness or lethargy, agitation, diaphoresis, and hypoglycemia. Our study is the first to use a wide range of national data to describe the clinical characteristics that differentiate the toxicologic exposure to biguanides and sulfonylureas. Sulfonylurea exposure is commonly seen via unintentional exposure, while metformin exposure is frequently seen via intentional exposure. Sulfonylurea toxicity is more likely to cause agitation, dizziness or vertigo, tremor, diaphoresis, and hypoglycemia, while metformin exposure induces abdominal pain, acidosis, diarrhea, nausea, vomiting, and elevated creatinine.
Identifiants
pubmed: 35398707
pii: S0735-6757(22)00182-6
doi: 10.1016/j.ajem.2022.03.023
pii:
doi:
Substances chimiques
Hypoglycemic Agents
0
Sulfonylurea Compounds
0
Metformin
9100L32L2N
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-177Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Authors declare no conflict of interest.